Loading…
Loading…
Definitive Healthcare Corp. (NASDAQ: DH - Get Free Report) has received a consensus rating of "Reduce" from the nine analysts that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and one has assigned a strong buy recommendation to the company.
Definitive Healthcare Corp. (DH) Q2 2026 Earnings Call Transcript
Definitive Healthcare Corp. (DH) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.07 per share a year ago.
Definitive Healthcare NASDAQ: DH reported second-quarter fiscal 2026 revenue and profitability that met or exceeded its guidance ranges, while management pointed to improving retention trends and continued investments in artificial intelligence products as key components of its plan to return to growth.
Unifying claims, provider, consumer, and expert data enables organizations to uncover growth opportunities and make faster, better-informed decisions Unifying claims, provider, consumer, and expert data enables organizations to uncover growth opportunities and make faster, better-informed decisions
FRAMINGHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced that it will report financial results for its second quarter ended June 30, 2026, on Monday, August 10, 2026 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results.
Definitive Healthcare (DH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FRAMINGHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that in connection with the hiring of one senior leader, the Human Capital Management and Compensation Committee (the “Committee”) of Definitive Healthcare's Board of Directors granted inducement awards. The Committee granted Srinivas Attipalli of the Company, Definitive Healthcare's new SVP and Head of AI & Data - Product, an inducement award consisting of 1,063,830 time-based restricted stock units (“RSUs”), effective July 24, 2026. These awards were individually negotiated and granted as an inducement material to Mr. Attipalli's respective commencement of employment with Definitive Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4).